Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) Invested Capital (2022 - 2025)

Historic Invested Capital for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $396.6 million.

  • Immunocore Holdings' Invested Capital rose 495.91% to $396.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.6 million, marking a year-over-year increase of 495.91%. This contributed to the annual value of $360.7 million for FY2024, which is 220.34% down from last year.
  • Immunocore Holdings' Invested Capital amounted to $396.6 million in Q3 2025, which was up 495.91% from $388.5 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Invested Capital registered a high of $396.6 million during Q3 2025, and its lowest value of $338.9 million during Q4 2022.
  • For the 4-year period, Immunocore Holdings' Invested Capital averaged around $369.8 million, with its median value being $368.8 million (2023).
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 883.44% in 2023, then plummeted by 220.34% in 2024.
  • Quarter analysis of 4 years shows Immunocore Holdings' Invested Capital stood at $338.9 million in 2022, then grew by 8.83% to $368.8 million in 2023, then dropped by 2.2% to $360.7 million in 2024, then increased by 9.94% to $396.6 million in 2025.
  • Its Invested Capital was $396.6 million in Q3 2025, compared to $388.5 million in Q2 2025 and $378.5 million in Q1 2025.